Zydus Saroglitazar shows positive Phase 3 results in rare liver disease PBC, US filing planned in 2026

Zydus Therapeutics reveals encouraging outcomes from Saroglitazar's clinical trial. The drug targets Primary Biliary Cholangitis. The EPICS-III trial demonstrates improved liver function in patients. These patients did not respond to standard treatment. Zydus plans to seek US regulatory approval in early 2026. Saroglitazar is a novel treatment option. It addresses bile acid toxicity and liver inflammation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vjFK0CD
via IFTTT

Read More

Murae Organisor plans to boost agro-sector presence under Rs 80-cr investment strategy

Murae Organisor Ltd is set to bolster its agro-sector presence with an Rs 80 crore investment in R&D and infrastructure. The plan includes establishing an Agro R&D Laboratory, developing processing and packaging infrastructure, and implementing digital traceability systems. This strategic move follows the company's proposed qualified institutional placement (QIP) of up to Rs 80 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Fk4UOZS
via IFTTT

Read More

IHH Healthcare to add 2,000 beds in India by 2028

IHH Healthcare plans to expand its presence in India by adding approximately 2,000 new beds by 2028. This expansion will be facilitated through its subsidiaries, Fortis Healthcare and Gleneagles Healthcare, which currently operate 35 hospitals with over 5,000 beds across 11 states.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QxuECrd
via IFTTT

Read More

FDA approves updated COVID-19 shots but limits access for some kids and adults

U.S. regulators have approved updated COVID-19 shots from Pfizer, Moderna, and Novavax, but access is now limited for younger adults and children to those with high-risk conditions. Pfizer's vaccine is no longer available for children under 5, while Novavax's shot is restricted to those 12 and older. These changes reflect a shift in U.S.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4z301L6
via IFTTT

Read More

Catching heart disease in its quietest moments in Type 2 diabetes

Early detection of heart disease in Type 2 diabetes is crucial, as it often develops silently. Advanced tests like high-sensitivity blood work, imaging, and genetic screening can identify hidden risks before symptoms appear. Proactive measures, including lifestyle changes and personalized medication, can significantly reduce cardiovascular complications and improve outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6ByGFHL
via IFTTT

Read More

Drug, medtech companies fear GST changes may squeeze funds

Pharma and medtech sectors are concerned about upcoming Goods and Services Tax changes. They anticipate higher operating costs and working capital issues. Rajiv Nath suggests a balanced GST approach for equipment and consumables. Federation of Pharma Entrepreneurs urges lower GST on APIs to avoid inverted duty structure. MSMEs fear blocked funds and slowed growth due to tax imbalances.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZTCn0xy
via IFTTT

Read More

Dr Reddy's expects new GST framework to address critical issues impacting pharma sector

Dr Reddy's Laboratories anticipates that the new Goods and Services Tax structure will address existing challenges. It will also create a rationalised tax framework for the pharmaceutical sector. The Association of Indian Medical Device Industry seeks to retain 12 percent GST for most consumables. It also wants 5 percent rate on costly equipment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LN2v7zg
via IFTTT

Read More

Dr Reddy's launches novel drug for chronic constipation management

Dr Reddy's Laboratories has introduced Colozo, a generic drug for chronic constipation in India. This medication, Linaclotide, is approved by the USFDA. It addresses chronic idiopathic constipation and irritable bowel syndrome. This launch strengthens Dr Reddy's gastrointestinal segment. It follows the introduction of BixiBat in India last year. The company aims to improve patient care and serve 1.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xGuUVvT
via IFTTT

Read More

Sampre Nutrition inks 3-year manufacturing pact with Rama Exports for nutraceuticals

Sampre Nutrition has partnered with Rama Exports in a manufacturing agreement to produce nutraceuticals and food products. Sampre Nutrition will handle manufacturing, supply, quality assurance, and packaging, while Rama Exports will purchase the finished goods over a three-year contract. This agreement is projected to generate Rs 15 crore in business, boosting Sampre Nutrition's revenue and strengthening its operations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HPuawKj
via IFTTT

Read More

GSK enters into oncology segment; launches therapies for gynaecological cancers

GlaxoSmithKline Pharmaceuticals has entered the oncology segment in India, introducing Jemperli and Zejula for gynaecological cancers. These therapies address unmet needs in endometrial and ovarian cancer treatment, with incidence projected to rise significantly by 2045. Jemperli offers targeted immunotherapy for advanced endometrial cancer, while Zejula provides first-line maintenance therapy for advanced ovarian cancer.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UfkMqiF
via IFTTT

Read More

From Clinic to Crisis: How Poor Follow-Up Fuels the Type 2 Diabetes Epidemic

Many individuals with diabetes in India are unaware of their condition, leading to missed opportunities for early treatment and increased health risks. Regular follow-up appointments are crucial for monitoring progress, identifying early warning signs, and adjusting treatment plans to prevent complications. Skipping these check-ups can result in silent damage to vital organs and faster progression of the disease.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/P2zhxni
via IFTTT

Read More

India's healthcare chains set their hearts on foreign patients

Indian healthcare providers are aggressively pursuing a larger share of the medical tourism market, fueled by a significant increase in foreign patients seeking treatment. Tourist arrivals for medical reasons have surged, with hospitals now attracting patients from Europe and the UK, in addition to traditional markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aplvDgO
via IFTTT

Read More

Global PE firms tighten grip on India’s $80-billion hospital sector

India's private hospital sector has seen a significant shift towards ownership by global private equity firms in the last five years, especially after the Covid-19 pandemic. This trend is reshaping the healthcare market, attracting investments from entities like Temasek, TPG, and KKR.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HKgSMQC
via IFTTT

Read More

IMA warns of misuse, mis-prescription of new weight-loss drugs, such as Wegovy and Mounjaro

The Indian Medical Association is raising concerns about the misuse of weight-loss drugs like Wegovy and Mounjaro, urging stricter prescription controls. They plan to petition the health ministry and drug regulator, advocating for prescriptions to be limited to certified endocrinologists or diabetologists. Rampant prescriptions by cosmetologists and other non-specialists are fueling concerns about potential side effects and improper usage.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UcrkMaY
via IFTTT

Read More

Novo Nordisk warns patients after theft of weight-loss, diabetes drugs

Novo Nordisk urges customers to purchase medications solely from authorized pharmacies with valid prescriptions after a theft of products, including semaglutide and insulin treatments, during transportation. The company is cooperating with authorities and reinforcing supply chain safeguards. CDSCO has issued an alert, advising caution and vigilance in procuring Novo Nordisk products from trusted sources due to potential compromised quality.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vU71Iaq
via IFTTT

Read More

CDSCO issues alert on Novo drugs after reported theft

The CDSCO has alerted healthcare professionals and consumers about stolen Novo Nordisk products, including semaglutide and insulin injectables. These products, requiring specific temperature control (2-8°C), may be compromised if improperly stored. The regulator has instructed state drug control offices to monitor the market and take action under the Drugs and Cosmetics Act, 1940, while police investigate the theft during transit.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GRFfUEp
via IFTTT

Read More

Substantial cancer drugs beyond ambit of current price control mechanisms: Parliamentary panel

A parliamentary panel has urged for broader price controls on cancer drugs, noting that many remain unaffordable. The committee recommends regular market assessments, quality monitoring of generic medicines, and enhanced domestic research. Streamlining regulatory pathways and fostering public-private collaboration are crucial for improving access to novel therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vsfilqK
via IFTTT

Read More

Stricter shelf life rule a bitter pill to swallow for pharma companies

A new regulation by the CDSCO mandates that exported drugs must have at least 60% shelf life remaining, causing significant losses to the Indian pharmaceutical industry. Manufacturers are now forced to destroy stocks to comply with this rule. The industry is urging for a revision, citing unnecessary losses and questioning the need when importing countries permit shorter shelf lives.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dGhcLye
via IFTTT

Read More

Drugmaker Novo Nordisk freezes hiring for non-critical jobs

Novo Nordisk, the maker of Wegovy, has initiated a global hiring freeze for non-critical roles amid increasing competition and pressure from Eli Lilly. This decision follows a profit warning that led to a significant drop in market value and the appointment of a new CEO, Mike Doustdar, who is considering cost-saving measures, including potential layoffs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RsJVMF5
via IFTTT

Read More

Natco Pharma launches generic drug with 180-day exclusivity in US

Natco Pharma has launched Bosentan tablets, a generic version of Tracleer, in the US for treating pulmonary arterial hypertension in young patients. This launch comes with 180-day exclusivity. Lupin Ltd. is Natco's marketing partner for this product. The drug had estimated sales of USD 10 million in the US for the 12 months ended June this year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/J5HvGMB
via IFTTT

Read More

When the heart and sugar collide: The overlooked risk in Type 2 diabetes

Type 2 diabetes significantly elevates the risk of heart disease due to high blood sugar damaging arteries, leading to plaque buildup and reduced blood flow. Recognizing subtle symptoms like chest pain or shortness of breath is crucial for early intervention. Simple lifestyle adjustments, including a balanced diet, regular exercise, and stress management, can significantly protect heart health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tNAOYfd
via IFTTT

Read More

Aurobindo Pharma closing in on $5.5b Zentiva buyout

Largest Indian pharma M&A in final lap; PE firm GTCR only other contender. A portfolio company of Advent International, Zentiva will significantly boost Aurobindo’s European footprint.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Sa0FGJC
via IFTTT

Read More

Indian drugmakers seek exemption for generics from US supplies probe

Indian pharmaceutical industry representatives met with Union Commerce Minister Piyush Goyal. They requested the US government to exclude generic drugs from its investigation into pharmaceutical imports. The probe, under Section 232, raises concerns about supply chain disruptions. This discussion occurs amidst India-US trade negotiations and potential US tariffs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/J3tBKf9
via IFTTT

Read More

Glenmark, Alembic Pharma, Sun Pharma recall products in US: USFDA

Glenmark, Alembic Pharmaceuticals, and Sun Pharma are recalling various products in the US due to manufacturing issues, according to the USFDA. Glenmark is recalling Carvedilol tablets due to nitrosamine impurity and Theophylline tablets for failed dissolution. Alembic is recalling Doxepin capsules for a similar impurity issue, while Sun Pharma recalls Spironolactone tablets due to aluminum contamination.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/82y5NSr
via IFTTT

Read More

Alembic gets USFDA nod for generic drug for skin condition

Alembic Pharmaceuticals has secured USFDA approval for its generic Tretinoin Cream USP (0.025%), a treatment for acne vulgaris. This ANDA is therapeutically equivalent to Bausch Health US, LLC's Retin-A Cream. The market size for Tretinoin cream USP (0.025%) is estimated at USD 94 million for the twelve months ending June 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rQjfEAB
via IFTTT

Read More

Aurobindo Pharma expects China plant to break even at EBITDA level this year

Aurobindo Pharma anticipates its China facility will achieve break-even by Q3 FY26. Production is ramping up after commencing operations in November 2024. The company invested USD 145 million in the facility. Aurobindo Pharma also invested in US facilities and plans to file for products in the US and Europe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Hs24qbj
via IFTTT

Read More

Food Chained: How weight-loss drugs are changing India’s eating habits and forcing restaurants to take note

New diabetes and obesity drugs, like Mounjaro and Ozempic, are changing people's relationships with food. While these drugs help control diabetes and promote weight loss by altering taste and reducing hunger, some users experience a loss of enjoyment in eating and even develop food anxieties.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qipXT2j
via IFTTT

Read More

Max Healthcare to nearly double capacity to 9,500 beds by 2028 after strong quarterly growth

Max Healthcare Institute aims to nearly double its bed capacity to 9,500 by 2028 through brownfield and greenfield expansions, following a 35% increase to 5,000 beds last year. The company reported a 27% jump in first-quarter revenue to Rs 2,574 crore and a 17% rise in net profit to Rs 345 crore, driven by higher occupancy and international patient revenue.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tES5J9n
via IFTTT

Read More

Cohance Lifesciences announces $10 million investment in US-based arm

Cohance Lifesciences is investing USD 10 million to expand bioconjugation capabilities at its US subsidiary, NJ Bio, enhancing its ADC solutions. This investment aims to support innovators from early development through late-phase clinical supply. Additionally, Cohance is investing Rs 23 crore in a new oligonucleotide building block manufacturing facility in Hyderabad, part of a broader capacity expansion program.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/G6moSWY
via IFTTT

Read More

From burden to breakthrough: Reimagining the #WeightofDiabetes through meaningful conversations with your doctor

Effectively managing type 2 diabetes involves more than just medication; it requires open communication with healthcare providers to address weight, heart health, and emotional well-being. Proactive conversations can clarify confusion, uncover barriers, and empower individuals to take charge of their health, preventing crises and promoting resilience through personalized care and support.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/n6QNrjO
via IFTTT

Read More

Intas Pharma completes acquisition of UDENYCA biosimilar for $558 million

Intas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. This acquisition strengthens Intas's position as a global leader in pegfilgrastim. Accord BioPharma, Intas's U.S. specialty business, will continue commercializing UDENYCA to reduce infection risk in cancer patients undergoing myelosuppressive chemotherapy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tpuhbM4
via IFTTT

Read More

Lupin ties up with Sandoz to commercialise biosimilar product

Lupin has partnered with Sandoz Group AG to commercialize its biosimilar ranibizumab across multiple regions, with Sandoz handling commercialization in the EU (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia. Lupin will manufacture the product and manage regulatory submissions. Sandoz also gains exclusive rights for commercialization in Canada.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9LHTCSq
via IFTTT

Read More

Chemists seek ban on quick commerce sale of prescription drugs

The All India Organisation of Chemists and Druggists (AIOCD) has appealed to Amit Shah. They want immediate action against e-pharmacies and quick commerce platforms. These platforms are selling prescription medicines online. AIOCD says this poses a public health risk. They are concerned about drug abuse, especially among young people. AIOCD also highlights the issue of ghost prescriptions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XILAdwq
via IFTTT

Read More

Asia Healthcare Holdings to invest Rs 400 crore in Asian Institute of Nephrology and Urology to double hospital network

Asia Healthcare Holdings will invest Rs 400 crore in Asian Institute of Nephrology and Urology. The investment will occur over the next 4-5 years. AINU plans to expand by opening 13 hospitals in Tier 2 cities. This expansion includes cities like Patna and Bhubaneshwar. The total investment will reach Rs 1,000 crore by FY30.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FypJzrY
via IFTTT

Read More

Pfizer launches next-gen vaccine for pneumococcal disease

Pfizer has introduced its 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India, offering protection against 20 serotypes responsible for a majority of pneumococcal diseases. This single-dose vaccine provides timely and proactive protection for all adults, including those with chronic conditions, potentially eliminating the need for a second dose.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T8l6hCc
via IFTTT

Read More

Welcure Drugs & Pharma board to consider share split, bonus issue this month

Welcure Drugs & Pharmaceuticals is set to consider a stock split of 1:10 and a bonus issue of 1:1 in its upcoming board meeting on August 22. This decision follows strong financial results in Q1 FY26, with revenue from operations reaching Rs 299.91 crore and net profit surging to Rs 23.29 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MIrfW2R
via IFTTT

Read More

Zydus Lifesciences gets USFDA approval for angina, high blood pressure drug

Zydus Lifesciences has secured USFDA approval to market Diltiazem Hydrochloride tablets, used for treating angina and high blood pressure, in strengths of 30 mg, 60 mg, 90 mg, and 120 mg. The medication, a calcium-channel blocker, relaxes blood vessels, easing the heart's workload and improving blood flow.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4CdspvA
via IFTTT

Read More

Retinal disorders a public health crisis, need immediate prioritisation, say experts

Mission Vision, a public health initiative, has launched in India to combat the escalating crisis of vision loss due to Diabetic Retinopathy. The initiative aims to increase awareness, improve screening and treatment access, and integrate eye care into routine diabetes management.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UecTf9s
via IFTTT

Read More

Managing diabetes in a country obsessed with quick fixes: A scientific perspective

Diabetes management faces challenges due to patients' preference for quick fixes over sustainable lifestyle changes. These shortcuts, like extra medication or unproven supplements, offer temporary relief but neglect long-term disease control. Shifting mindsets requires holistic approaches, personalized support, and collaborative healthcare to promote lasting healthy habits and prevent complications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wmz1MyF
via IFTTT

Read More

Govt gives BIS exemption to parts used in medical devices for now

The steel ministry has temporarily suspended its notification requiring Indian standards compliance for raw materials used in medical device manufacturing, offering relief to the industry. They will issue no-objection certificates for importing special stainless steel grades and allow foreign suppliers six months to obtain Bureau of Indian Standards registration.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xAzXsHv
via IFTTT

Read More

Biocon sees GLP-1 weight-loss therapy as a future growth driver

Biocon will strengthen its insulin business while advancing in GLP-1 therapies, with semaglutide in Phase-III trials and a planned 2027 India launch. CEO Shreehas Tambe said both portfolios are complementary. Biocon aims to leverage its insulin experience for GLP-1 success, following US FDA approval for insulin aspart and India approval for liraglutide. External risks remain a key concern.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dw4pEIK
via IFTTT

Read More

Medical device firms sound the alarm over new steel standards

Earlier, foreign suppliers only needed BIS certification for finished steel products. Under the new rule, materials like hot rolled steel, ingots manufactured by other countries for Indian buyers will have to get BIS certification. The manufacturers have written to the ministry of steel seeking exemption for the import of stainless steel capillary without BIS certification.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FurWfSZ
via IFTTT

Read More

Weight-loss drug Mounjaro crosses Rs 100 crore sales in 4 months

The drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker PharmaTrac. If this month-on-month doubling of sales continues, Mounjaro’s revenue could cross Rs 500 crore by March, experts estimate.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xLPVHcg
via IFTTT

Read More

Novo Nordisk's Wegovy, Mounjaro sales in India double on month in July

Sales of Novo Nordisk's Wegovy and Eli Lilly's Mounjaro in India doubled in July, according to Pharmarack data. Wegovy, launched in June, saw sales more than double to 5,000 units, while Mounjaro sales also doubled to 157,000 units. Mounjaro's sales have soared 15 times since its March launch in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AhPSKaq
via IFTTT

Read More

Executive order by US administration excludes Pharma sector from immediate tariff imposition: Indian Pharmaceutical Alliance

The Indian pharmaceutical sector has been excluded from immediate US tariff hikes due to the importance of generic medicines for affordable healthcare in the United States. This follows President Trump's imposition of a 25% tariff on India over Russian oil purchases, raising the total tariff to 50%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bkQCuVn
via IFTTT

Read More

Indian pharma on alert as US mulls higher drug tariffs

Indian drug makers are assessing the potential consequences of additional tariffs imposed by the US in response to India's oil purchases from Russia. While previous tariffs spared pharmaceuticals, uncertainty prevails due to frequent policy changes. Companies are exploring mitigation strategies like price adjustments and technology transfer to the US, anticipating manageable impacts on medicine access.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JTxi1wE
via IFTTT

Read More

More heart attacks in diabetes? Here’s what you should know

Type 2 diabetes elevates the risk of heart issues, but advancements offer hope. New treatments not only manage blood sugar but also promote weight loss, lower blood pressure, and improve cholesterol, reducing heart-related hospitalizations. Addressing obesity is crucial, and consulting a doctor about comprehensive diabetes and heart health management is recommended.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GwPz60k
via IFTTT

Read More

Indian generics wave next year set to sink obesity drug price

Leading Indian drugmakers are preparing to launch generic versions of semaglutide by March. Analysts predict a significant price drop, potentially up to 80%. This will make the drug more accessible to obese and diabetes patients. The domestic weight-loss drug market is expected to grow substantially. Semaglutide patent expiry will trigger price erosion and increased adoption.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/l0384zN
via IFTTT

Read More

Eris Lifesciences eyes ‘good’ share in semaglutide generics, says COO

Eris Lifesciences plans to lead in generic semaglutide drugs. The patent for Novo Nordisk's drug expires in India in March 2026. Eris aims for a significant market share. Several Indian drugmakers are also preparing to launch generic versions. Eris has experience with diabetes drugs. The company hopes to leverage its existing portfolio. It includes orals, insulin, and GLP-1.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0wQPGY2
via IFTTT

Read More

Pharma tariffs may go as high as 250%, says Trump

U.S. President Donald Trump said new tariffs on imported pharmaceuticals will start small but could rise to 250% within 18 months to boost domestic production. He also plans to announce fresh duties on foreign semiconductors, aiming to reduce U.S. reliance on overseas supply chains.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xS1FQAT
via IFTTT

Read More

Mind, muscle, and metabolism: The power of holistic diabetes management

Managing diabetes holistically involves more than just blood sugar control, encompassing lifestyle factors like diet, exercise, and mental well-being. Small changes, such as increasing fiber intake and regular walking, can significantly impact health. Understanding hormones like GLP-1 and insulin, along with addressing stress and sleep, are crucial for comprehensive diabetes care and improved overall well-being.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/THnDtI9
via IFTTT

Read More

Corner Office Conversation with The New Leaders of Indian Pharma

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yagzUpd
via IFTTT

Read More

Manipal Hospitals seeks CCI nod to acquire Sahyadri Hospitals for about Rs 6,400 cr

Manipal Hospitals is planning to acquire Sahyadri Hospitals. The deal is estimated at around Rs 6,400 crore. Manipal has sought approval from the Competition Commission of India. This acquisition will significantly expand Manipal's presence in western India. It will also increase Manipal's total bed count to approximately 12,000. Sahyadri Hospitals currently operates 11 hospitals in Maharashtra.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Iv06Knp
via IFTTT

Read More

70% enrolment of participants for Phase III clinical trial of dengue vaccine completed: Centre

India achieves a milestone in dengue prevention. The DengiAll vaccine trial sees 70% participant enrollment. ICMR leads the multi-center study across 20 Indian sites. The budget is approximately Rs 1.3 to 1.5 crore per site. Dengue cases are rising, with over 5 lakh confirmed in 2024. The government monitors outbreaks and provides support to states.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZYMrA1o
via IFTTT

Read More